Insmed Incorporated

Bridgewater – November 04, 2026 -- Insmed Incorporated (Nasdaq: INSM) will put management in front of investors at two healthcare conferences within a span of 15 days, starting November 16 in London.

Insmed management to present at Jefferies in London on November 16

The company will appear at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026, at 9:00 a.m. ET.

Evercore session in Coral Gables is set for December 1

Management will then present at the Evercore 9th Annual Healthcare Conference in Coral Gables, Florida, on Tuesday, December 1, 2026, at 9:10 a.m. ET.

Both presentations will be webcast live and archived for 30 days

Both events will be webcast live through the investor relations section of Insmed's website. Each webcast will remain archived for 30 days after the live event ends.

Bridgewater, N.J. – – October 05, 2026 -- Insmed Incorporated (Nasdaq: INSM) announced that Chief Financial Officer Sara Bonstein will step down on October 30, 2026, after nearly seven years in the role, during which the company raised more than $4.2 billion in capital.

Bonstein exits after helping raise $4.2 billion for Insmed

Bonstein will remain CFO through the company's third-quarter 2026 earnings report and will participate in the earnings call on October 29, 2026, before departing the following day. Insmed has launched a search with an executive search firm to identify her successor. The company stated the transition is unrelated to any disagreement over accounting practices, financial statements, internal controls, or operations.

Bridgewater, N.J. – September 21, 2026 -- The U.S. Food and Drug Administration has accepted Insmed Incorporated's supplemental New Drug Application (sNDA) for full approval of ARIKAYCE (amikacin liposome inhalation suspension) to treat Mycobacterium avium complex (MAC) lung disease, granting Priority Review with a PDUFA target action date of January 28, 2027.

FDA sets January 28, 2027 decision date under Priority Review

The Priority Review designation applies to therapies that could offer significant improvement in safety or efficacy for serious conditions. Insmed said full approval would allow ARIKAYCE, administered via PARI Pharma's Lamira Nebulizer System, to reach patients earlier in their disease course, including newly diagnosed cases and those with recurrent infections.

Bridgewater, N.J. – September 09, 2026 -- Insmed Incorporated (Nasdaq: INSM) has issued inducement equity awards to 128 newly hired employees, a move tied to its ongoing workforce expansion in the biopharmaceutical sector.

Insmed grants 115,320 restricted stock units to new hires as employment inducement

The awards, approved by Insmed's Compensation Committee, were granted on September 09, 2026, under the company's 2025 Inducement Plan. The plan is structured to comply with Nasdaq Listing Rule 5635(c)(4), which permits equity grants as a material inducement for new employees without requiring shareholder approval.